Gene Expression Profiling (GEP) Signatures to Advance Your Research

TIS • PAM50 • LST • Other Molecular Signatures

Gene expression profiling (GEP) signatures consists of sets of genes that are characteristic of a particular disease, tissue, cell type, cell state or biological perturbation. The significant diagnostic, predictive and prognostic value of GEP signatures places them at the forefront of translational and precision medicine research. Thousands of signatures have been generated and annotated, and have been valuable in the interpretation of gene expression datasets generated from heterogeneous samples. Only a small number of signatures, however, have been shown to have clinical significance. 

NanoString has a long and rich history of providing innovative gene expression analysis solutions that support biology driven RNA expression analysis across multiple disease and research areas, including GEP signatures with demonstrated clinical utility in immuno-oncology, breast cancer, and lymphoma. 

Your Trusted Partner in Translational Research

NanoString has been developing translational research tools for over 20 years and believes in partnering with scientists to advance their research. Recognizing the importance of gene expression profiling signatures in advancing disease biomarkers to improve patient outcomes, NanoString has partnered in the development and analytical validation of three clinically relevant signatures.

Established and Clinically-Relevant Gene Expression Profiling Signatures


  • Tumor Inflammation Signature (TIS)
  • 18 functional genes known to be associated with response to PD-1/PD-L1 blockade and other immune-oncology targeted therapies
  • Measures key pathways of Immune Biology: IFN-ү signaling, antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance genes
  • Quantifies the magnitude of a peripherally suppressed, adaptive immune response in the tumor microenvironment


  • 50-gene signature that allows for the classification of breast cancer into four biologically distinct subtypes and used to generate a prognostic score
  • Defines 4 prototypical subtypes: Basal, Her2-Enriched, Luminal B and Luminal A
  • Risk of Recurrence (ROR) score and risk category available (if annotations provided)


  • Lymphoma Subtyping Test (LST) Signature
  • 15-gene signature based on the Leukemia and Lymphoma Molecular Profiling Project Lymph2Cx assay, also known as the Cell-of-Origin signature
  • The LST report includes the Linear Predictor Score (LPS) and the DLBCL cell of origin subtype: GCB, ABC, or Unclassified

Other Gene Expression Profiling Signatures

In addition to three clinically relevant signatures, select Nanostring panels offer the ability to look at numerous other gene expression profiling signatures that can accelerate your research.

View example data analysis report: IO360 Time Series Demo Report


View example data analysis report: BC360 TNBC Demo Report

RUO Assays Available as Single Signature CodeSets

NanoString also offers select CodeSets that can generate data for individual signature reports. These CodeSets only contain the genes within the signature along with target/reference genes.

Lymphoma Subtyping Test Signature (RUO)

Contains probes for the 20 genes within the LST signature, 15 target genes and 5 reference genes.

PAM50 Signature (RUO)

Contains probes for the 50 genes within the PAM50 signature as well as 8 reference genes.

Gene Expression Signature Data Analysis Reports

Gene expression profiling signature data analysis reports are available through NanoString’s Data Analysis Service. NanoString’s Data Analysis Service enables scientists and researchers to analyze and interpret differential gene expression results without the need for bioinformatics or programming skills. Visit the site for more details.

Data analysis reports offer access to validated Oncology gene expression profiling signatures

Want to Learn More?

Fill out the form below to learn more about our GEP solutions.

Related Resources

Product Bulletin PanCancer IO 360 Panel- Product Bulletin
Product Bulletin Breast Cancer 360 – Product Bulletin
Flyer Clinically relevant Gene Expression Algorithm Signatures for Clinical Studies – Flyer
Blog Post Statistically Significant Results without the Headache. Q&A with Sarah Church, Ph.D., Senior Scientist at NanoString.